LONDON, United Kingdom: EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3 million in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (‘DTIF’). Poolbeg Pharma (AIM: POLB) is a clinical stage infectious disease pharmaceutical company. Taking place over three years, the collaboration between Poolbeg…